Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

ARPA-H awards up to USD 4.9m to establish ibogaine clinical trial framework for PTSD

13 November 2026 · By · Wire by Fusion42

Published

13 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 13 November 2026 · Fusion42 review

The US Advanced Research Projects Agency for Health (ARPA-H) has awarded up to USD 4.9 million to fund the establishment of a clinical trial framework for ibogaine to treat serious mental illnesses such as PTSD, aiming to support Investigational New Drug Applications to the FDA and enable the first US clinical trials for psychiatric indications of ibogaine.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

New regulatory pathways for ibogaine trials open the US market for psychoactive therapies targeting PTSD. You can now plan for faster entry if your biotech venture focuses on mental health treatments with complex safety profiles.

◆ Coverage

1 source · 13 Nov 2026

◆ Related on Wire

◆ Topics

Biotechibogaineclinical-trialsptsd-treatmentarpa-hmental-healthus-fda